Toggle SGML Header (+)

Section 1: 8-K (FORM 8K)






Washington, D.C. 20549









Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of report (Date of earliest event reported): November 13, 2018





(Exact Name of Registrant as Specified in Its Charter)


Minnesota 001-34839 41-1732920

(State or Other Jurisdiction of 


(Commission File Number)

(I.R.S. Employer Identification 



500 Sixth Avenue NW 

New Prague, MN 56071 

(Address of Principal Executive Offices)(Zip Code)


(952) 758-9299 

(Registrant’s Telephone Number, Including Area Code)


Not Applicable 

(Former Name or Former Address, if Changed Since Last Report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 2.02Results of Operations and Financial Condition


On November 13, 2018, Electromed, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2018. The full text of the press release is attached as Exhibit 99.1.


Item 9.01Financial Statements and Exhibits


(d) Exhibits:


99.1Press Release dated November 13, 2018.


The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.






Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 13, 2018 By: /s/ Jeremy T. Brock  
  Name: Jeremy T. Brock  
  Title: Chief Financial Officer  






Exhibit Number   Description   Method of Filing
99.1   Press Release dated November 13, 2018   Furnished Electronically


(Back To Top)

Section 2: EX-99.1 (PRESS RELEASE DATED NOVEMBER 13, 2018)


Exhibit 99.1






Electromed, Inc. Announces Fiscal 2019 First Quarter Financial Results


-- 15.4% year-over-year increase in revenue --


New Prague, Minnesota – November 13, 2018 – Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2018 (“Q1 FY 2019”).


Q1 FY 2019 Highlights


Net revenue increased 15.4% to $7.3 million from $6.3 million during the three months ended September 30, 2018 (“Q1 FY 2018”).

Gross profit rose 18.2% to $5.5 million from $4.7 million in Q1 FY 2018.

Operating income grew 100.6% to $199,000 from $99,000 in Q1 FY 2018.

Net income expanded 90.7% to $154,000, or $0.02 per diluted share, from $81,000, or $0.01 per diluted share, in Q1 FY 2018.

Cash flow from operating activities totaled $303,000, compared to $328,000 in Q1 FY 2018.

Field sales employees grew to 49 at the end of Q1 FY 2019 from 41 at the end of Q1 FY 2018.


Kathleen Skarvan, President and Chief Executive Officer of Electromed, commented, “We achieved strong top- and bottom-line growth in the first quarter of fiscal 2019, driven by a 13.8% year-over-year increase in home care revenue. Both referrals and approvals rose year-over-year, reflecting our expanded sales force, ongoing excellence in our reimbursement operations and continuing efforts to advance physician awareness and education surrounding the benefits of high frequency chest wall oscillation therapy (“HFCWO”) with our SmartVest® device. We also are pleased to report that sales in our institutional segment this quarter rose 42.0% year-over-year, driven primarily by our strategic focus on integrated delivery networks (IDNs).”


Ms. Skarvan continued, “Looking ahead, we believe Electromed can achieve double-digit revenue growth with our strategies of providing superior device features and benefits along with world-class service, leading in bronchiectasis clinical studies and improving education and awareness of bronchiectasis prevalence and the need for the SmartVest Airway Clearance System to effectively treat these patients. We believe earnings growth will improve over the next few years as we focus on sales force productivity improvements and tighter SG&A cost control. We continue to emphasize greater frequency of visits to targeted clinics and hospital systems that more actively prescribe HFCWO therapy, versus greenfield locations with limited sales activity and generating higher quality referrals for higher referral to approval conversion rates. We remain as excited as ever about the large and growing bronchiectasis market and dedicated to improving quality-of-life and outcomes for patients with compromised pulmonary function.”


Q1 FY 2019 Review


Net revenue increased 15.4% to $7.3 million in Q1 FY 2019 from $6.3 million in Q1 FY 2018, primarily driven by higher home care revenue. Home care revenue rose 13.8% to $6.7 million in Q1 FY 2019 from $5.9 million in Q1 FY 2018, primarily due to growth in referrals and approvals driven by a larger field sales staff and continued improvements in the Company’s reimbursement operations that led to a greater referral to approval percentage.




Gross profit increased 18.2% to $5.5 million, or 76.2% of net revenue, in Q1 FY 2019 from $4.7 million, or 74.4% of net revenue, in Q1 FY 2018. The increase in gross profit resulted primarily from an increase in home care revenue.


Operating expenses, which include selling, general and administrative (“SG&A”) as well as research and development (“R&D”) expenses, totaled $5.3 million, or 73.4% of revenue, in Q1 FY 2019 compared with $4.6 million, or 72.8% of revenue, in the same period of the prior year. SG&A expenses increased 16.7% to $5.3 million in Q1 FY 2019 from $4.5 million in Q1 FY 2018, primarily due to higher payroll and compensation-related expenses and increased travel, meals and entertainment expenses which were driven by the expansion of our sales force. R&D expenses totaled $68,000 in Q1 FY 2019 compared to $71,000 in Q1 FY 2018.


Operating income increased 100.6% to $199,000 in Q1 FY 2019 from $99,000 in Q1 FY 2018, primarily due to increased gross profit driven by higher revenue, which was partially offset by costs related to the expansion of our sales force.


Net income before income tax expense rose 123.7% to $212,000 in Q1 FY 2019 from $95,000 in Q1 FY 2018.


Net income increased 90.7% to $154,000, or $0.02 per diluted share, in Q1 FY 2019, from $81,000, or $0.01 per diluted share, in Q1 FY 2018. In Q1 FY 2019, income tax expense totaled $58,000, compared to $14,000 in the same period of the prior year.


Financial Condition


Electromed’s balance sheet at September 30, 2018 included cash of $7.7 million, long-term debt including current maturities of $1.1 million, working capital of $18.9 million, and shareholders’ equity of $23.0 million.


Conference Call


Management will host a conference call on November 14, 2018 at 8:00 am CT (9:00 am ET) to discuss Q1 FY 2019 financial results and other matters.


Interested parties may participate in the call by dialing:


(877) 407-9753 (Domestic)

(201) 493-6739 (International)


The conference call will also be accessible via the following link:


For those who cannot listen to the live broadcast, an online webcast replay will be available in the Investor Relations section of Electromed’s web site at:




About Electromed, Inc.


Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about Electromed can be found at


Cautionary Statements


Certain statements in this release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “believe,” “estimate,” “expect,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to: the competitive nature of our market; risks associated with expansion into international markets; changes to Medicare, Medicaid, or private insurance reimbursement policies; new drug or pharmaceutical discoveries; changes to health care laws; changes affecting the medical device industry; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; our ability to protect and expand our intellectual property portfolio; our ability to renew our line of credit or obtain additional credit as necessary; our ability to develop new sales channels for our product; and general economic and business conditions, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent reports on Form 10-Q and Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.


Electromed, Inc.   The Equity Group Inc.
Jeremy Brock, Chief Financial Officer   Kalle Ahl, CFA
(952) 758-9299   (212) 836-9614
[email protected]   [email protected]
    Devin Sullivan
    (212) 836-9608
    [email protected]




Financial Tables Follow:


Electromed, Inc. 

Condensed Balance Sheets 


   September 30, 2018   June 30, 2018 
Current Assets          
Cash  $7,747,129   $7,455,844 
Accounts receivable (net of allowances for doubtful accounts of $45,000)   11,545,915    11,811,308 
Contract assets   835,831    776,338 
Inventories   2,840,407    2,486,848 
Prepaid expenses and other current assets   415,476    751,541 
Total current assets   23,384,758    23,281,879 
Property and equipment, net   2,965,526    3,091,242 
Finite-life intangible assets, net   641,039    649,103 
Other assets   5,907    5,907 
Deferred income taxes   517,000    364,000 
Total assets  $27,514,230   $27,392,131 
Liabilities and Shareholders’ Equity          
Current Liabilities          
Current maturities of long-term debt  $1,089,120   $1,101,043 
Accounts payable   850,477    810,644 
Accrued compensation   1,111,438    1,269,849 
Income taxes payable   156,640    397,390 
Warranty reserve   730,000    760,000 
Other accrued liabilities   542,513    464,357 
Total current liabilities   4,480,188    4,803,283 
Commitments and Contingencies          
Shareholders’ Equity          
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,329,826 and 8,288,659 issued and outstanding at September 30, 2018 and June 30, 2018, respectively   83,298    82,887 
Additional paid-in capital   15,243,494    14,953,103 
Retained earnings   7,707,250    7,552,858 
Total shareholders’ equity   23,034,042    22,588,848 
Total liabilities and shareholders’ equity  $27,514,230   $27,392,131 





Electromed, Inc. 

Condensed Statements of Operations


     For the Three Months Ended
September 30,
   2018    2017  
Net revenues  $7,275,883   $6,304,322 
Cost of revenues   1,733,051    1,613,604 
Gross profit   5,542,832    4,690,718 
Operating expenses          
Selling, general and administrative   5,275,755    4,520,905 
Research and development   68,137    70,663 
Total operating expenses   5,343,892    4,591,568 
Operating income   198,940    99,150 
Interest income (expense), net   13,452    (4,199)
Net income before income taxes   212,392    94,951 
Income tax expense   58,000    14,000 
Net income  $154,392   $80,951 
Income per share:          
Basic  $0.02   $0.01 
Diluted  $0.02   $0.01 
Weighted-average common shares outstanding:          
Basic   8,260,131    8,200,167 
Diluted   8,637,990    8,614,633 




Electromed, Inc. 

Condensed Statements of Cash Flows


   Three Months Ended September 30, 
   2018   2017 
Cash Flows From Operating Activities          
Net income  $154,392   $80,951 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation   164,856    164,070 
Amortization of finite-life intangible assets   29,850    28,258 
Amortization of debt issuance costs   979    2,197 
Share-based compensation expense   257,234    190,385 
Deferred taxes   (153,000)   (30,000)
Changes in operating assets and liabilities:          
Accounts receivable   265,393    376,479 
Contract assets   (59,493)   (397)
Inventories   (349,439)   118,187 
Prepaid expenses and other assets   336,065    (180,740)
Income tax receivable       (226,582)
Income tax payable   (240,750)   (156,524)
Accounts payable and accrued liabilities   (103,253)   (38,157)
Net cash provided by operating activities   302,834    328,127 
Cash Flows From Investing Activities          
Expenditures for property and equipment   (10,429)   (95,011)
Expenditures for finite-life intangible assets   (21,786)   (7,436)
Net cash used in investing activities   (32,215)   (102,447)
Cash Flows From Financing Activities          
Principal payments on long-term debt including capital lease obligations   (12,902)   (12,397)
Issuance of common stock upon exercise of options   33,568     
Net cash provided by (used in) financing activities   20,666    (12,397)
Net increase in cash   291,285    213,283 
Beginning of period   7,455,844    5,573,709 
End of period  $7,747,129   $5,786,992 






(Back To Top)